论文部分内容阅读
目的:探讨艾迪注射液联合沙利度胺对老年多发性骨髓瘤患者血清中APRIL、β2-m和TPO水平变化的影响及其临床意义。方法:选取我院收治的老年多发性骨髓瘤患者80例,根据治疗方案不同分为常规组及试验组。常规组患者采用长春新碱静、盐酸肾上腺素及醋酸地塞米松治疗,试验组患者采用艾迪注射液联合沙利度胺治疗。观察并比较两组患者治疗前后骨髓浆细胞数、M蛋白、血红蛋白、免疫功能、肾功能及血清APRIL、β2-m和TPO水平的变化情况。结果:与常规组比较,试验组采用患者的免疫功能及肾功能获得明显改善,肿瘤细胞活性得到显著抑制,差异具有统计学意义(P<0.05)。与常规组比较,试验组患者骨髓浆细胞数、M蛋白、血肌酐、尿素氮水平降低,血红蛋白及CD4+/CD8+比值升高,血清APRIL、β2-m和TPO水平降低,差异具有统计学意义(P<0.05)。结论:艾迪注射液联合沙利度胺可降低多发性骨髓瘤患者的肿瘤细胞活性,增强患者免疫力,且副作用小,值得临床推广应用。
Objective: To investigate the effect of Aidi Injection and thalidomide on the changes of serum APRIL, β2-m and TPO levels in elderly patients with multiple myeloma and its clinical significance. Methods: 80 cases of elderly patients with multiple myeloma admitted to our hospital were selected and divided into routine group and experimental group according to different treatment options. Patients in the conventional group were treated with vincristine, epinephrine hydrochloride and dexamethasone acetate. Patients in the test group were treated with Aidi Injection combined with thalidomide. The changes of plasma cell number, M protein, hemoglobin, immune function, renal function, serum APRIL, β2-m and TPO levels in the two groups before and after treatment were observed and compared. Results: Compared with the conventional group, the immune function and renal function of the experimental group were significantly improved, and the tumor cell activity was significantly inhibited (P <0.05). Compared with the control group, the number of plasma cells, M protein, serum creatinine, blood urea nitrogen, the ratio of hemoglobin and CD4 + / CD8 +, the levels of serum APRIL, β2-m and TPO in the test group were significantly lower than those in the control group P <0.05). Conclusion: Aidi injection combined with thalidomide can reduce the activity of tumor cells in patients with multiple myeloma and enhance the immunity of patients with less side effects, which is worthy of clinical application.